Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)
Immune checkpoint inhibitor
Acute interstitial nephritis with long latency.
AIN
ModerateOpen →
PD-L1 immune checkpoint inhibitor
Cosibelimab
Unloxcyt · PD-L1 inhibitor
PD-L1 blockade for cutaneous SCC — watch for late immune interstitial nephritis
ModeratePD-L1 checkpoint inhibitor era (2020s) · approved 2024
Metastatic cutaneous squamous cell carcinoma (mCSCC) not eligible for curative surgery or radiationLocally advanced cutaneous squamous cell carcinoma (laCSCC) not eligible for curative surgery or radiation
Signature kidney injury
Acute Interstitial Nephritis
Representative incidence3%
Drug-specific renal data are limited. In the pivotal phase 1 metastatic CSCC cohort (n=78), immune-related adverse events occurred in 23.1% of patients (grade 3 in 2.6%; no grade 4/5), with no nephritis-specific signal reported and a favorable overall safety profile. By class, immune-mediated nephritis/AKI with checkpoint inhibitors is uncommon: a 2023 systematic review and meta-analysis of 27 studies (24,048 patients) found a pooled all-cause AKI incidence of ~5.7%, with clinically significant immune-mediated nephritis substantially lower (roughly 1-3%), and anti-PD-L1 agents tending toward the lower end of that range versus CTLA-4 or combination regimens.
Source: Class-level estimate from Liu et al., Front Immunol 2023 (PMID 37313406): pooled ICI-associated AKI incidence 5.7%; drug-specific phase 1 safety from Clingan et al., J Immunother Cancer 2023 (PMID 37848259).
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
0%incidence
SeverityModerate
ReversibilityPartially reversible
Evidence0 refs
Nephron map
Glomerulus
Distal Tubule / Collecting Duct
InterstitiumSupporting tissue around the tubules
Acute Interstitial Nephritis
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Mechanism of kidney injury
The dominant renal mechanism is immune-related: PD-L1 blockade reactivates self-reactive effector T cells and breaks peripheral tolerance, producing a CD4/CD8 T-cell-rich acute (tubulo)interstitial nephritis. Contributing mechanisms described for the PD-1/PD-L1 axis include loss of tolerance to self renal antigens, reactivation of T cells previously primed by nephritogenic co-medications (PPIs, NSAIDs, antibiotics), and increased PD-L1 expression by tubular epithelium. Less commonly, immune dysregulation can produce glomerular lesions (e.g., podocytopathy/minimal-change-like or other immune-complex glomerulonephritis) and electrolyte disturbances. There is no appreciable direct tubular toxicity from the antibody itself.
Clinical presentation
Typically an asymptomatic, often delayed rise in serum creatinine detected on routine labs. Sterile pyuria, subnephrotic proteinuria, white-cell casts, and eosinophilia may be present but are inconsistent; classic allergic-AIN features (rash, fever, eosinophilia) are frequently absent. Concurrent extrarenal immune-related adverse events (dermatitis, colitis, thyroiditis, hepatitis) raise suspicion. Glomerular involvement, when it occurs, may present with new or worsening proteinuria.
Anticancer mechanism
Cosibelimab is a fully human IgG1 monoclonal antibody that binds programmed death-ligand 1 (PD-L1), blocking its interaction with the PD-1 and B7-1 (CD80) receptors and thereby restoring T-cell anti-tumor activity. Unlike effector-silenced anti-PD-L1 antibodies, it retains a functional Fc domain and can additionally engage antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against PD-L1-expressing tumor cells.
Management
Per checkpoint-inhibitor immune-related adverse event guidance: for grade 2 nephritis (creatinine 1.5-3x baseline) hold cosibelimab and start corticosteroids (prednisone ~0.5-1 mg/kg/day); for grade 3-4 (creatinine >3x baseline or dialysis-requiring) permanently discontinue and give methylprednisolone 1-2 mg/kg/day with slow taper over at least 4-6 weeks. Exclude pre-renal, obstructive, and other causes; involve nephrology and consider kidney biopsy when the diagnosis is uncertain or steroids fail. Steroid-refractory cases may warrant additional immunosuppression (e.g., mycophenolate). Rechallenge only after recovery and careful risk-benefit discussion.
Risk factors
- Pre-existing chronic kidney disease
- Older age
- Concurrent proton pump inhibitor use
- Concurrent NSAID use
- Concurrent diuretics or ACEI/ARB use
- Combination checkpoint blockade (e.g., added CTLA-4 inhibitor)
- Other extrarenal immune-related adverse events
- Prior or concurrent nephritogenic drug exposure
Prevention
- Baseline and periodic monitoring of serum creatinine and urinalysis before each cycle
- Review and minimize concurrent nephritis-associated drugs (PPIs, NSAIDs)
- Maintain euvolemia and avoid nephrotoxin stacking
- Early nephrology referral and low threshold for kidney biopsy when AKI is unexplained
- Hold the drug and treat per immune-related adverse event guidelines at first sign of significant creatinine rise
Note · Cosibelimab (Unloxcyt; cosibelimab-ipdl) received first FDA approval in December 2024 and is the first anti-PD-L1 therapy approved for advanced cutaneous SCC. Drug-specific nephrotoxicity literature is essentially absent; this profile reasons from the registrational phase 1 safety data and from the broader PD-1/PD-L1 checkpoint-inhibitor nephrotoxicity literature. Educational content, not medical advice.
Clinical depth
Renal dose adjustment
No starting-dose adjustment for renal impairment is established; as a ~150 kDa IgG1 monoclonal antibody, cosibelimab is not cleared by the kidney, and mild-to-moderate renal impairment is not expected to alter exposure. Dosing is a fixed flat regimen (1200 mg IV every 3 weeks). Management of nephrotoxicity is by holding or discontinuing the drug and immunosuppression rather than dose reduction. Data in severe renal impairment or dialysis are lacking.
Dialyzability & ESKD dosing
Not dialyzable. Large therapeutic monoclonal antibodies are not removed by hemodialysis or peritoneal dialysis owing to their size; no dosing change is anticipated for patients on dialysis, though formal data are absent.
Differential diagnosis
Distinguish immune-mediated AIN from pre-renal azotemia (volume depletion, cancer-related), obstruction, contrast- or chemotherapy-associated ATN, hypercalcemia, and tumor-related causes. Concurrent PPI/NSAID-induced AIN can be hard to separate and may be synergistic. New proteinuria suggests a glomerular immune lesion. The delayed timing, sterile pyuria/white-cell casts, and accompanying extrarenal irAEs favor checkpoint-inhibitor AIN; kidney biopsy is the reference standard when feasible.
Monitoring
- Serum creatinine/eGFR at baseline and before each infusion
- Urinalysis with microscopy (pyuria, casts) and quantified proteinuria (UPCR/UACR)
- Assessment for concurrent extrarenal immune-related adverse events
- Medication review for PPIs/NSAIDs and other nephrotoxins
- Serum electrolytes including potassium and magnesium
Key trials & series
- NCT03212404 — pivotal open-label, multicenter phase 1 study; metastatic CSCC cohort ORR 47.4% (Clingan et al., J Immunother Cancer 2023)
- Locally advanced CSCC cohort of the same phase 1 program supporting FDA approval (2024)
Clinical pearls
- Renal toxicity is a class effect, not drug-specific: expect immune-mediated AIN, not direct tubular injury.
- Anti-PD-L1 agents like cosibelimab generally carry lower nephritis risk than CTLA-4 or combination checkpoint regimens.
- ICI-AIN is often a delayed, asymptomatic creatinine rise — surveillance labs, not symptoms, usually make the diagnosis.
- Always review for PPIs and NSAIDs: they are common AIN co-culprits that potentiate checkpoint-inhibitor nephritis.
- Corticosteroids are the mainstay; many cases recover at least partially, but late or severe presentations can leave residual CKD.
- Drug-specific renal data are thin given recent (2024) approval — class data and registrational safety must fill the gap, and that uncertainty should be stated honestly.
Beyond the kidney
Class-level context for the major non-renal toxicities of pd-l1 immune checkpoint inhibitors.
Endocrine
Thyroiditis, hypophysitis, diabetes
- Thyroiditis, hypophysitis, type-1 diabetes
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Immune colitis
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Immune hepatitis
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Pneumonitis
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Rash, vitiligo, rarely SJS/TEN
Evidence
5 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkEfficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.Clingan P, Ladwa R, Brungs D, et al. · Journal for Immunotherapy of Cancer 2023 · PMID 37848259Pivotal phase 1 registrational trial (NCT03212404) for the metastatic CSCC cohort; source of drug-specific safety/immune-related adverse event data used to anchor the renal risk estimate.PMIDCosibelimab: First Approval.Lee A · Drugs 2025 · PMID 40167969Regulatory and pharmacology summary of cosibelimab's first FDA approval, including its functional Fc/ADCC mechanism and approved indications.PMIDPD-L1 Inhibitor Cosibelimab for Cutaneous Squamous Cell Carcinoma: Comprehensive Evaluation of Efficacy, Mechanism, and Clinical Trial Insights.Idris OA, Westgate D, Saadaie Jahromi B, et al. · Biomedicines 2025 · PMID 40299523Comprehensive review of cosibelimab efficacy, mechanism (PD-L1 blockade plus ADCC), and trial data contextualizing its safety relative to other PD-1/PD-L1 agents.PMIDIncidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Liu C, Wei W, Yang L, et al. · Frontiers in Immunology 2023 · PMID 37313406Meta-analysis (27 studies, 24,048 patients) providing the class-level AKI incidence (5.7%), median onset (~108 days), and risk factors used to estimate cosibelimab's renal risk in the absence of drug-specific data.PMIDThe Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?Franzin R, Netti GS, Spadaccino F, et al. · Frontiers in Immunology 2020 · PMID 33162990Mechanistic review of checkpoint-inhibitor nephrotoxicity establishing acute tubulointerstitial nephritis as the recurrent histologic lesion and detailing the immune mechanisms applied to this PD-L1 agent.